The JAVELIN Renal 101, a randomized phase III trial of avelumab (10 mg/kg every two weeks) plus axitinib versus sunitinib as first-line therapy in 886 patients with mRCC [126] showed superior ORR (55.2% vs. 25.5%, respectively) and PFS (13 vs. 8.4 months, respectively) across tumor PD-L1 status in patients receiving avelumab plus axitinib compared to those receiving sunitinib [126]. Here, CD274 is linked to neoplasm.